-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although the current CD19-CAR-T cell therapy for relapsed or refractory acute B-lymphocytic leukemia (R/R B-ALL) has achieved a high complete remission (CR) rate, there are still some patients in CD19-CAR -The recurrence of T cell therapy and the detection of CD22 expression have become an urgent problem to be solved.
In response to the above problems, Dr.
Zhao Defeng, the director of Beijing Boren Hospital's Tong Chunrong team, performed CD22-CAR-T cell therapy on 19 adult patients with R/R B-ALL, including 18 patients who had received CD19-CAR-T cell therapy and 1 case.
For patients who have lost CD19 antigen and have not been treated with CD19-CAR-T cells, the efficacy of CD22-CAR-T cells in the treatment of adult R/R B-ALL will be evaluated.
The study was selected for the poster presentation of the 26th European Annual Meeting of Hematology (2021 EHA).
The editor organizes its main content as follows for the reference of readers.
The CAR-T cells used in this study are made of second-generation CARs that are encoded by lentiviral vectors that combine activation and costimulatory signals (CD3ζ chain and 4-1BB).
All patients received fludarabine and/or cyclophosphamide before infusion.
On the 30th day after the infusion, the minimal residual disease (MRD) of the fusion gene was detected by FCM and quantitative PCR, and the treatment effect was evaluated.
The last follow-up was as of October 24, 2020.
The median age of the 19 patients was 30 years (range: 18-63 years), and 7 of them received allogeneic hematopoietic stem cell transplantation.
All patients received ≥1×105/kg CD22-CAR-T cells.
Evaluation was performed on the 30th day after the infusion.
Of the 19 patients, 15 (78.
9%) achieved CR or complete remission with incomplete recovery of platelet count (CRi).All patients developed cytokine release syndrome (CRS), but most only developed mild CRS and neurotoxicity.
Among the 15 patients who achieved CR and CRi, 8 received allogeneic hematopoietic stem cell transplantation after CD22-CAR-T cell therapy.
These patients were still in remission 4-39.
7 months after transplantation; the other 7 patients did not Receiving transplantation, 1 patient relapsed 1 month later, and 6 patients were still in remission 4-26.
5 months after the infusion.
Of the 4 unresolved patients, 3 died of disease progression, and 1 received a salvage transplant and survived for 4.
6 months.
The results of this study suggest that CD22-CAR-T cells are more effective in inducing remission in adult R/R B-ALL patients, and CD22-CAR-T cell therapy followed by bridging transplantation treatment can make CR patients get 4-39.
7 months Continuous relief.
Experts comment that in recent years, CD19-CAR-T cell therapy for R/R B-ALL has achieved a high rate of remission, but there are still some patients who relapse after treatment.
Most of the tumor cell membranes express CD22 on the surface of the relapsed patients.
, Then, CD22-CAR-T cell therapy can also be used as a new targeted therapy method.
The study showed that for those patients who have relapsed after CD19-CAR-T cell therapy, or patients who do not express CD19 themselves, with CD22-CAR-T cell therapy, the remission rate of one treatment can reach 78.
9%.
In addition, during the treatment process, the CRS response was small, and all patients could tolerate it.
There were no deaths due to severe CRS reactions.
Allogeneic hematopoietic stem cell transplantation was available for patients who achieved remission.
Some patients received allogeneic hematopoietic stem cell transplantation.
So far The longest disease-free survival was 39.
7 months.
In the field of treatment of R/R ALL, CAR-T cell therapy has made a major breakthrough.
CD22-CAR-T cell therapy provides new opportunities for relapsed patients who have received CD19-CAR-T cell therapy or who do not express CD19.
CAR-T cell therapy target.
The remission rate of nearly 80% proves that CD22-CAR-T cell therapy is effective.
After CD22-CAR-T cell therapy for R/R B-ALL remission, bridging transplantation provides a new opportunity for patients to heal.
Zhao Defeng, Deputy Chief Physician, Master of the Second Military Medical University, engaged in clinical work in the Department of Hematology in the former Navy General Hospital for more than 20 years and published more than 10 papers in Chinese and English.
He has rich clinical experience in hematology, and has in-depth understanding of the diagnosis and treatment of various types of anemia, acute and chronic leukemia, lymphoma, multiple myeloma and other common hematology diseases and new developments.
For refractory and relapsed leukemia, lymphoma, The diagnosis and treatment of lymphoma of the central nervous system has its own unique insights.
Good at diagnosis and treatment of leukemia, lymphoma, treatment of complications after bone marrow transplantation, and immunotherapy of malignant hematological tumors.
Reference source: Zhao Feng, et al.
CD22-TAGETED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA.
2021 EHA Annual Meeting.
Abstract EP344.
Stamp "Read the original" and we will make progress together
In response to the above problems, Dr.
Zhao Defeng, the director of Beijing Boren Hospital's Tong Chunrong team, performed CD22-CAR-T cell therapy on 19 adult patients with R/R B-ALL, including 18 patients who had received CD19-CAR-T cell therapy and 1 case.
For patients who have lost CD19 antigen and have not been treated with CD19-CAR-T cells, the efficacy of CD22-CAR-T cells in the treatment of adult R/R B-ALL will be evaluated.
The study was selected for the poster presentation of the 26th European Annual Meeting of Hematology (2021 EHA).
The editor organizes its main content as follows for the reference of readers.
The CAR-T cells used in this study are made of second-generation CARs that are encoded by lentiviral vectors that combine activation and costimulatory signals (CD3ζ chain and 4-1BB).
All patients received fludarabine and/or cyclophosphamide before infusion.
On the 30th day after the infusion, the minimal residual disease (MRD) of the fusion gene was detected by FCM and quantitative PCR, and the treatment effect was evaluated.
The last follow-up was as of October 24, 2020.
The median age of the 19 patients was 30 years (range: 18-63 years), and 7 of them received allogeneic hematopoietic stem cell transplantation.
All patients received ≥1×105/kg CD22-CAR-T cells.
Evaluation was performed on the 30th day after the infusion.
Of the 19 patients, 15 (78.
9%) achieved CR or complete remission with incomplete recovery of platelet count (CRi).All patients developed cytokine release syndrome (CRS), but most only developed mild CRS and neurotoxicity.
Among the 15 patients who achieved CR and CRi, 8 received allogeneic hematopoietic stem cell transplantation after CD22-CAR-T cell therapy.
These patients were still in remission 4-39.
7 months after transplantation; the other 7 patients did not Receiving transplantation, 1 patient relapsed 1 month later, and 6 patients were still in remission 4-26.
5 months after the infusion.
Of the 4 unresolved patients, 3 died of disease progression, and 1 received a salvage transplant and survived for 4.
6 months.
The results of this study suggest that CD22-CAR-T cells are more effective in inducing remission in adult R/R B-ALL patients, and CD22-CAR-T cell therapy followed by bridging transplantation treatment can make CR patients get 4-39.
7 months Continuous relief.
Experts comment that in recent years, CD19-CAR-T cell therapy for R/R B-ALL has achieved a high rate of remission, but there are still some patients who relapse after treatment.
Most of the tumor cell membranes express CD22 on the surface of the relapsed patients.
, Then, CD22-CAR-T cell therapy can also be used as a new targeted therapy method.
The study showed that for those patients who have relapsed after CD19-CAR-T cell therapy, or patients who do not express CD19 themselves, with CD22-CAR-T cell therapy, the remission rate of one treatment can reach 78.
9%.
In addition, during the treatment process, the CRS response was small, and all patients could tolerate it.
There were no deaths due to severe CRS reactions.
Allogeneic hematopoietic stem cell transplantation was available for patients who achieved remission.
Some patients received allogeneic hematopoietic stem cell transplantation.
So far The longest disease-free survival was 39.
7 months.
In the field of treatment of R/R ALL, CAR-T cell therapy has made a major breakthrough.
CD22-CAR-T cell therapy provides new opportunities for relapsed patients who have received CD19-CAR-T cell therapy or who do not express CD19.
CAR-T cell therapy target.
The remission rate of nearly 80% proves that CD22-CAR-T cell therapy is effective.
After CD22-CAR-T cell therapy for R/R B-ALL remission, bridging transplantation provides a new opportunity for patients to heal.
Zhao Defeng, Deputy Chief Physician, Master of the Second Military Medical University, engaged in clinical work in the Department of Hematology in the former Navy General Hospital for more than 20 years and published more than 10 papers in Chinese and English.
He has rich clinical experience in hematology, and has in-depth understanding of the diagnosis and treatment of various types of anemia, acute and chronic leukemia, lymphoma, multiple myeloma and other common hematology diseases and new developments.
For refractory and relapsed leukemia, lymphoma, The diagnosis and treatment of lymphoma of the central nervous system has its own unique insights.
Good at diagnosis and treatment of leukemia, lymphoma, treatment of complications after bone marrow transplantation, and immunotherapy of malignant hematological tumors.
Reference source: Zhao Feng, et al.
CD22-TAGETED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA.
2021 EHA Annual Meeting.
Abstract EP344.
Stamp "Read the original" and we will make progress together
